ORIC Pharmaceuticals Expands Team with Stock Option Grants
In a strategic move to strengthen its workforce, ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage oncology company, has recently announced substantial stock option grants to three new non-executive employees. This initiative reflects ORIC's ongoing dedication to attracting and retaining top talent in the rapidly advancing field of cancer treatment.
Details of the Inducement Grants
On September 3, 2024, ORIC granted a total of 173,200 non-qualified stock options along with 28,900 restricted stock units. These grants serve as both compensation and a testament to the company's commitment to fostering a collaborative and growth-oriented workplace. To encourage long-term dedication, 25% of the stock options will vest after one year, with the remaining options vesting monthly thereafter. Similarly, the restricted stock units will vest in structured phases over a three-year period.
Commitment to Compliance
The Compensation Committee of ORIC’s Board of Directors authorized these inducement grants, in accordance with Nasdaq Rule 5635(c)(4). This process ensures compliance with all regulatory requirements, reinforcing the ethical standards that ORIC Pharmaceuticals upholds.
Overview of ORIC Pharmaceuticals
ORIC Pharmaceuticals is dedicated to revolutionizing cancer care through the development of targeted therapies that address the complexities of therapeutic resistance. Some of their notable product candidates include:
- ORIC-114: A brain-penetrant inhibitor designed to treat cancers with EGFR and HER2 mutations.
- ORIC-944: An innovative allosteric inhibitor targeting the polycomb repressive complex 2 (PRC2), particularly relevant for prostate cancer.
- ORIC-533: An orally administered small molecule inhibitor that targets CD73, which is crucial in the adenosine pathway-related resistance mechanisms in multiple myeloma.
In addition to these candidates, ORIC is actively advancing precision medicine initiatives to address various resistance mechanisms in oncology.
A Growth-Focused Future
ORIC Pharmaceuticals is not only expanding its team but also enhancing its product pipeline. With a solid strategy and a dedicated workforce, the company aims to navigate the complexities of drug development. Their focus extends beyond existing candidates to the exploration of potential new therapies that could significantly change treatment paradigms for cancer patients.
Contact Information
For more information about ORIC Pharmaceuticals and its initiatives, please contact:
Dominic Piscitelli, Chief Financial Officer
Email: dominic.piscitelli@oricpharma.com
Email: info@oricpharma.com
Frequently Asked Questions
What are the recent stock option grants by ORIC Pharmaceuticals?
ORIC Pharmaceuticals has granted 173,200 stock options and 28,900 restricted stock units to new employees, aimed at promoting their long-term commitment to the company.
What is the purpose of these inducement grants?
The inducement grants are intended to attract and retain skilled professionals in the competitive field of oncology.
What are the conditions for the stock options to vest?
Options will vest 25% after one year, with the remaining options vesting monthly thereafter, while restricted stock units will vest in phases over three years.
How does ORIC ensure compliance with Nasdaq regulations?
All stock option grants are approved by ORIC’s Compensation Committee in line with Nasdaq Rule 5635(c)(4) to ensure compliance and uphold company standards.
What types of products does ORIC Pharmaceuticals develop?
ORIC focuses on innovative therapies that address specific mechanisms of resistance in cancer, including drugs that target EGFR, HER2, and the adenosine pathway.
